Mood stabilizers are defined by their clinical effect rather than a single biological mechanism
In short: Mood stabilizers are a diverse group of medications used to manage the intense highs and lows of bipolar disorder. While they share the goal of preventing relapses and reducing symptoms like racing thoughts, they act through different pathways, ranging from naturally occurring elements to repurposed epilepsy drugs.
The term mood stabilizer describes a therapeutic outcome rather than a specific pharmacological class. These drugs are primarily used to treat bipolar disorder, helping to manage manic episodes and prevent the return of symptoms that might otherwise require hospitalization. Beyond bipolar disorder, they are sometimes used to treat schizoaffective disorder or to manage impulsivity and aggression in other psychiatric conditions. Because they work by modulating brain receptors that regulate neurotransmitters, patients often need to take them consistently for several weeks before noticing significant effects.
Lithium, the classic mood stabilizer, has been FDA-approved since 1970. It remains unique among psychiatric medications for its proven anti-suicidal properties and its ability to decrease all-cause mortality in people with mood disorders. However, it requires careful management; healthcare providers must routinely monitor blood levels to keep them within a therapeutic range, as high levels can be toxic. Common side effects include lethargy and weight gain, while long-term use may impact thyroid and kidney function.
Anticonvulsants, originally developed for epilepsy, represent another major category. Drugs like valproate are often used as first-line treatments for acute mania, though they carry risks such as liver dysfunction and teratogenic potential, leading to strict usage guidelines for women of childbearing age. Other agents, such as lamotrigine, are approved for maintenance therapy but not for acute mood episodes. Research into the pharmacogenomics of these drugs is ongoing, with recent studies suggesting that genetic liability for epilepsy may predict a better response to anticonvulsant mood stabilizers.
The landscape of treatment is evolving as clinicians navigate the balance between behavioral efficacy and side effects. In some cases, atypical antipsychotics are prescribed for their mood-stabilizing effects even when psychotic symptoms are absent. While researchers continue to investigate the potential of supplements like omega-3 fatty acids, the current clinical standard relies on a careful, monitored approach to medication, often requiring adjustments based on individual patient response and the emergence of adverse events.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: What Are Mood Stabilizers?
- Also: Mood stabilizer
- Also: Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.
To cite this card, link to https://intellectplus.co.uk/app/health-mood-stabilizer.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics